Insurability of HIV-positive people treated with antiretroviral therapy in Europe: Collaborative analysis of HIV cohort studies

AIDS

Volumn 27, Issue 10, 2013, Pages 1641-1655

  Kaulich Bartz, Josee ^a   Dam, Wayne ^a   May, Margaret T ^b   Lederberger, Bruno ^c   Widmer, Urs ^a   Phillips, Andrew N ^d   Grabar, Sophie ^e,f,g   Mocroft, Amanda ^d   Vilaro, Josep ^h   Van Sighem, Ard ⁱ   Moreno, Santiago ^j   Dabis, François ^k   Monforte, Antonella D'Arminio ^l   Teira, Ramon ^m   Ingle, Suzanne M ^b   Sterne, Jonathan A C ^b  

^a Swiss Re   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g Institut Cochin   (France)

^h Unit of Systemic Autoimmune Diseases   (Spain)

ⁱ STICHTING HIV MONITORING   (Netherlands)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k UNIVERSITÉ DE BORDEAUX   (France)

^l UNIVERSITY OF MILAN   (Italy)

^m HOSPITAL SIERRALLANA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; VIRUS TRANSMISSION; DRUG COMBINATION; EPIDEMIOLOGY; FRANCE; HIV INFECTIONS; ITALY; LIFE TABLE; MIDDLE AGED; RISK FACTOR; SPAIN; STATISTICS AND NUMERICAL DATA; SWITZERLAND; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INSURANCE, HEALTH; ITALY; LIFE TABLES; MALE; MIDDLE AGED; RISK FACTORS; SPAIN; SWITZERLAND; YOUNG ADULT;

EID: 84879072603     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283601199     Document Type: Article

References (28)

1. Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M, Bonarek M, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies 1. Lancet 2008; 372:293-299.
2. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-1960.
3. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
5. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
6. Anglaret X, Toure S, Gourvellec G, Tchehy A, Zio L, Zaho M, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 2004; 35:320-323.
7. Zwahlen M, Harris RJ, Hogg R, Costagliola D, May M, de WF, et al. Mortality of HIV-infected patients starting potent anti-retroviral therapy: Comparison with the general population in eight industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
8. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
9. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
10. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). IJE 2013 (in press) doi:10.1093/ije/dyt010.
11. McCullagh P, Nelder J. Generalized linear models: Chapman and Hall; 1989.
12. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 23:51-64.
13. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control AC 1974; 19:716-723.
14. 3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433-445.
15. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527-1535.
16. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
17. Gill MJ, May M, Lewden C, Saag M, Mugavero MJ, Reiss P, et al. Causes of death in HIV-1 infected patients treated with anti-retroviral therapy 1996-2006: collaborative analysis of 13 HIV cohorts. Clin Infect Dis 2010; 50:1387-1396.
18. Centers for Disease Control and Prevention. Establishing a Holistic Framework to Reduce Inequities in HIV, Viral Hepatitis, STDs, and Tuberculosis in the United States 2010. Available from: www.cdc.gov/socialdeterminants. [Accessed 16 August 2012].
19. Denning PH, DiNenno EA, Wiegand RE. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence-24 cities, United States, 2006-2007 (Reprinted from MMWR vol 60, p.1045; 2011).
20. JAMA 2011; 306:1320-1322.
21. US Department of Health & Human Services. How the Affordable Care Act Helps People Living with HIV/AIDS: 2011 and Beyond. Available from: http://www.healthcare.gov/news/factsheets/2011/11/hiv-aids11092011a.html. [Accessed 16 August 2012].
22. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren J, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335-343.
23. Dutch Association of Insurers. Insurability of people with HIV: a step closer 2005:28. Available from: http://www.verzekeraars.nl/UserFiles/File/ download/Hiv-engels.pdf. [Accessed 16 August 2012].
24. Dutch Asscoiation of Insurers. HIV Insurability Expanded: Report of the HIV Working Group 2009:38. Available from: http://www.verzekeraars.nl/UserFiles/ File/download/Rapport-Verzekerbaarheid-hiv%20-Engels-juni-2009.pdf. [Accessed 16 August 2012].
25. AIDS-HILFE SCHWEIZ. Life insurance policies for people living with HIV: International analysis. 2008:7. Available from: http://www.hivnet.org/downloads/ pdf/life-insurances-international-analysis.pdf. [Accessed 16 August 2012].
26. Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, et al. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med 2011; 12:583-593.
27. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
28. Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48:1138-1151.